儿童狼疮性肾炎临床特点及诊治现状

doi:10.12372/jcp.2023.23e0979

Abstract

Abstract:

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by immune dysregulation and autoantibody formation. With the progress of treatment, the survival rate of SLE patients has improved significantly. Even so, lupus nephritis (LN) is associated with high morbidity and mortality. At present, there is a lack of data on LN in children, and its diagnosis, treatment and monitoring are mainly based on guidelines for adults. Treatment is mainly based on hormones and immunosuppressants. Recently, biologics have been used to treat LN with good results and no obvious adverse reactions. This article reviews the progress of epidemiology, clinical features, pathogenesis, diagnosis and treatment of LN in children.

Key words: lupus nephritis, diagnosis, treatment, child

XIA Zhengkun, WANG Ren. Clinical characteristics and diagnosis of lupus nephritis in children[J].Journal of Clinical Pediatrics, 2023, 41(12): 881-886.

References 32

[1]	Chan EY, Yap DY, Wong WT, et al. Long-term outcomes of children and adolescents with biopsy-proven childhood-onset lupus nephritis[J]. Kidney Int Rep, 2022, 8(1): 141-150.
[2]	Diaz-Frias J, Badri T. Neonatal lupus erythematosus[M]. Treasure Island (FL): StatPearls Publishing, 2023.
[3]	Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: core curriculum 2020[J]. Am J Kidney Dis, 2020, 76(2): 265-281. doi: S0272-6386(19)31170-9 pmid: 32220510
[4]	Qiu S, Zhang H, Yu S, et al. Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis[J]. Pediatr Nephrol, 2022, 37(2): 367-376. doi: 10.1007/s00467-021-05164-y
[5]	Shi Y, Bi D, Wang Y, et al. Chinese SLE Treatment and Research Group Registry (CSTAR) XIV: the subjective well-being of patients with systemic lupus erythematosus[J]. Front Med (Lausanne), 2022, 9: 984183.
[6]	Gutiérrez-Suárez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1, 015 patients with juvenile-onset systemic lupus erythematosus[J]. Arthritis Rheum, 2006, 54(9): 2989-2996. doi: 10.1002/art.v54:9
[7]	Pinheiro SVB, Dias RF, Fabiano RCG, et al. Pediatric lupus nephritis[J]. J Bras Nefrol, 2019, 41(2): 252-265. doi: S0101-28002019000200252 pmid: 30465590
[8]	Weiss JE, Sison CP, Ilowite NT, et al. Flares in pediatric systemic lupus erythematosus[J]. J Rheumatol, 2007, 34(6): 1341-1344. pmid: 17477466
[9]	Aggarwal A, Phatak S, Srivastava P, et al. Outcomes in juvenile onset lupus: single center cohort from a developing country[J]. Lupus, 2018, 27(11): 1867-1875. doi: 10.1177/0961203318791046 pmid: 30071768
[10]	Yung S, Yap DY, Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies[J]. F1000 Res, 2020, 9: F1000 Faculty Rev-905.
[11]	Hagberg N, Rönnblom L. Interferon-α enhances the IL-12-induced STAT4 activation selectively in carriers of the STAT4 SLE risk allele rs7574865 [T][J]. Ann Rheum Dis, 2019, 78(3): 429-431. doi: 10.1136/annrheumdis-2018-213836 pmid: 30269051
[12]	Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal[J]. Ann Rheum Dis, 2019, 78(7): 947-956. doi: 10.1136/annrheumdis-2018-214856 pmid: 30782585
[13]	Peene I, Elewaut D. Changing the wolf from outside: how microbiota trigger systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(7): 867-869. doi: 10.1136/annrheumdis-2019-215221 pmid: 31076388
[14]	Kostopoulou M, Fanouriakis A, Bertsias G, et al. Annals of the rheumatic diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy[J]. Ann Rheum Dis, 2023, 82(6): 729-733. doi: 10.1136/ard-2023-223880
[15]	Frangou E, Chrysanthopoulou A, Mitsios A, et al. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A)[J]. Ann Rheum Dis, 2019, 78(2): 238-248. doi: 10.1136/annrheumdis-2018-213181 pmid: 30563869
[16]	Reid S, Alexsson A, Frodlund M, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus[J]. Ann Rheum Dis, 2020, 79(3): 363-369. doi: 10.1136/annrheumdis-2019-216227 pmid: 31826855
[17]	中华医学会儿科学分会免疫学组, 中华儿科杂志编辑委员会. 中国儿童系统性红斑狼疮诊断与治疗指南[J]. 中华儿科杂志, 2021, 59(12): 1009-1024.
[18]	Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J]. Ann Rheum Dis, 2020, 79(6): 713-723. doi: 10.1136/annrheumdis-2020-216924 pmid: 32220834
[19]	中华医学会儿科学分会肾脏学组. 狼疮性肾炎诊治循证指南(2016)[J]. 中华儿科杂志, 2018, 56(2): 88-94.
[20]	Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. Kidney Int, 2004, 65(2): 521-530. doi: 10.1111/j.1523-1755.2004.00443.x pmid: 14717922
[21]	Kaneko M, Jackson SW. Recent advances in immuno-therapies for lupus nephritis[J]. Pediatr Nephrol, 2023, 38(4): 1001-1012. doi: 10.1007/s00467-022-05670-7
[22]	Štambuk SK, Padjen I, Jukić NB, et al. Rescue treatment of severe lupus myocarditis and proliferative lupus nephritis with immunoadsorption[J]. Clin Rheumatol, 2023, 42(6): 1723-1725. doi: 10.1007/s10067-023-06611-x
[23]	Thakur N, Rai N, Batra P. Pediatric lupus nephritis-review of literature[J]. Curr Rheumatol Rev, 2017, 13(1): 29-36. doi: 10.2174/1573397112666160404124308 pmid: 27041086
[24]	Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial[J]. Ann Intern Med, 2015, 162(1): 18-26. doi: 10.7326/M14-1030 pmid: 25383558
[25]	Rovin BH, Solomons N, Pendergraft WF 3rd, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis[J]. Kidney Int, 2019, 95(1): 219-231. doi: S0085-2538(18)30628-8 pmid: 30420324
[26]	Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials[J]. Am J Kidney Dis, 2017, 70(3): 324-336. doi: 10.1053/j.ajkd.2016.12.008
[27]	van Gelder T, Lerma E, Engelke K, et al. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis[J]. Expert Rev Clin Pharmacol, 2022, 15(5): 515-529. doi: 10.1080/17512433.2022.2092470
[28]	中华医学会肾脏病学分会专家组. 利妥昔单抗在肾小球肾炎中应用的专家共识[J]. 中华肾脏病杂志, 2022, 38(2): 151-160. doi: 10.3760/cma.j.cn441217-20210615-00023
[29]	Yu C, Li P, Dang X, et al. Lupus nephritis: new progress in diagnosis and treatment[J]. J Autoimmun, 2022, 132: 102871. doi: 10.1016/j.jaut.2022.102871
[30]	Plüß M, Piantoni S, Tampe B, et al. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis[J]. Hum Vaccin Immunother, 2022, 18(5): 2072143. doi: 10.1080/21645515.2022.2072143
[31]	Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study[J]. Arthritis Rheumatol, 2014, 66(2): 379-389. doi: 10.1002/art.v66.2
[32]	ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study[J]. Arthritis Rheumatol, 2014, 66(11): 3096-3104. doi: 10.1002/art.v66.11

Clinical characteristics and diagnosis of lupus nephritis in children

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 32

Related Articles 15

Metrics

Comments

Recommended 0

[1]	ZOU Liping. Childhood encephalopathy: a group of diseases associated with various diseases [J]. Journal of Clinical Pediatrics, 2023, 41(9): 641-643.
[2]	ZHANG Weihua, ZOU Liping, REN Haitao, GUAN Hongzhi. Beware of the pitfalls in diagnosis and treatment of autoimmune encephalitis in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 644-649.
[3]	HOU Chi, CHEN Wenxiong, LIAO Yinting, WU Wenxiao, TIAN Yang, ZHU Haixia, PENG Bingwei, ZENG Yiru, WU Wenlin, CHEN Zongzong, LI Xiaojing. Clinical analysis of autoimmune glial fibrillary acidic protein astrocytopathy in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 656-660.
[4]	YANG Yating, CAI Yuehao, FANG Qiong, CHEN Lang, CHEN Qiaobin, LIN Zhi, WU Feifei, LIN Meng. Clinical analysis of idiopathic and symptomatic occipital lobe epilepsy in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 668-673.
[5]	HOU Ruolin, WU Jing, LI Ling. Pediatric autoimmune encephalitis with brain MRI showing meningeal thickening and enhancement [J]. Journal of Clinical Pediatrics, 2023, 41(9): 674-679.
[6]	WU Yuefang, SUN Yanling, WU Wanshui, DU Shuxu, LI Miao, SUN Liming. Analysis of prognostic factors and survival status of group 4 medulloblastoma in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 686-691.
[7]	SUN Juan, LI Haiying, JIA Peisheng, WANG Huaili. Clinical analysis of fulminant myocarditis in 12 children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 692-696.
[8]	Reviewer: WANG Chenhui, Reviser: YANG Hui. Research progress on early screening and diagnosis of Crohn's disease in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 708-714.
[9]	YU Hui. Resistance mechanism and treatment of carbapenem resistant Pseudomonas aeruginosa [J]. Journal of Clinical Pediatrics, 2023, 41(8): 561-565.
[10]	SHEN Nan, DU Bailu. Strategies for the diagnosis, treatment, and management of invasive fungal infections in children with hematologic neoplasms [J]. Journal of Clinical Pediatrics, 2023, 41(8): 571-577.
[11]	XU Beixue, LIU Quanbo. Clinical analysis of 195 children with invasive pulmonary fungal infection [J]. Journal of Clinical Pediatrics, 2023, 41(8): 584-588.
[12]	CHEN Hongyu, LIU Zihao, WANG Heping, LIAO Cuijuan, LI Li, WANG Wenjian, LAI Jianwei. Role of nontypeable Haemophilus influenzae biofilms in chronic pulmonary infection in children [J]. Journal of Clinical Pediatrics, 2023, 41(8): 589-593.
[13]	KANG Lei, GUO Fang, LI Lifang, BAI Xinfeng, CHENG Caiyun, XU Meixian. Value of metagenomic next-generation sequencing in children with visceral leishmaniasis associated with hemolytic histiocytosis [J]. Journal of Clinical Pediatrics, 2023, 41(8): 594-598.
[14]	SUN Zhicai, LIU Yuling, LI Xiaolin, PAN Xiaofen. Clinical analysis of 15 children with primary nephrotic syndrome complicated with adrenal crisis [J]. Journal of Clinical Pediatrics, 2023, 41(8): 610-612.
[15]	WANG Hongxia, PAN Xiang, LU Jun. Report a case of α-ketoadipic aciduria caused by compound heterozygous variant of DHTKD1 gene [J]. Journal of Clinical Pediatrics, 2023, 41(8): 624-628.